Ken Griffin
CMIIU

Ken Griffin’s CM Life Sciences II Inc. Unit CMIIU Stock Holding History

Ken Griffin’s Portfolio CMIIU Stock Details CMIIU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-38,357
Closed -$491K – 14859
2021
Q1 		$491K Buy
+38,357
New +$481K ﹤0.01% 9716

Other funds holding CMIIU

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
WMSA
Weiss Multi-Strategy Advisers New York $4.16B AUM 30.77% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
TCIM
TOMS Capital Investment Management New York $3.81B AUM 26.36% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
IM
Islet Management New York $49.1M AUM 17.59% 1-Year Est. Return

Ken Griffin's CMIIU Position: Q2 2021 in Review

Ken Griffin sold out of CM Life Sciences II Inc. Unit (CMIIU) in Q2 2021, closing a stake of 38,357 shares — an estimated $491K sold.

Ken Griffin first reported a position in CMIIU in Q1 2021 and held it in 1 quarter. The position peaked at $491K in Q1 2021. 38 funds tracked by Wall St. Rank hold CMIIU as of Q2 2021.

  • Ken Griffin reported no remaining CM Life Sciences II Inc. Unit position as of Q2 2021 after selling out during the quarter.
  • Ken Griffin sold 38,357 CM Life Sciences II Inc. Unit shares in Q2 2021, an estimated $491K.
  • Ken Griffin first reported a position in CM Life Sciences II Inc. Unit in Q1 2021 and held it in 1 quarter.
  • Ken Griffin's CM Life Sciences II Inc. Unit position peaked at $491K in Q1 2021.
  • 38 funds tracked by Wall St. Rank held CM Life Sciences II Inc. Unit as of Q2 2021.

Based on Citadel Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.